Drug intelligence / Profile preview

PDL-0101

Development stage: Unknown

Overview

**PDL-0101** is an investigational therapeutic being evaluated for the treatment of hyperlipidemias. It was studied in a pilot trial (NCT02582424) assessing safety and efficacy in patients with elevated triglycerides (150-495 mg/dl) and LDL cholesterol (≥70 mg/dl). The trial was an 8-week, multicenter, randomized, double-blind, placebo-controlled study targeting adults aged 25-85 in general good health.[5][7][9]

Beyond the preview

Go deeper on PDL-0101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDL-0101.

Explore the full profile